Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 48Lymphoma, Large B-Cell, Diffuse 36Multiple Myeloma 33Burkitt Lymphoma 32Lymphoma 30Leukemia, Myeloid, Acute 29Lymphoma, Non-Hodgkin 28Recurrence 26Breast Neoplasms 26Neoplasms 23Lymphoma, B-Cell 23Myelodysplastic Syndromes 20Lymphoma, Follicular 20Leukemia, Lymphocytic, Chronic, B-Cell 20Hodgkin Disease 17Triple Negative Breast Neoplasms 16Leukemia 16Ovarian Neoplasms 15Hematologic Neoplasms 15Neuroblastoma 14Melanoma 14Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 12Pancreatic Neoplasms 12Lymphoma, Mantle-Cell 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 12Leukemia, Biphenotypic, Acute 10Sarcoma 9Osteosarcoma 9Neoplasm Metastasis 9Lymphoma, B-Cell, Marginal Zone 9

Interventions

Paclitaxel 22Bevacizumab 20Carboplatin 19liposomal doxorubicin 14Specimen Handling 14Magnetic Resonance Spectroscopy 13olaparib 12Topotecan 9Gemcitabine 9Biopsy 8pembrolizumab 7Taxes 6Immunoglobulin G 6Disulfides 6niraparib 4mirvetuximab soravtansine 4cediranib 4Doxorubicin 4oregovomab 3Nivolumab 3Cyclophosphamide 3sarilumab 2rucaparib 2cemiplimab 2berzosertib 2adavosertib 2Oxaliplatin 2Docetaxel 2Cisplatin 2Biosimilar Pharmaceuticals 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × Cyclophosphamide × 90 days × Clear all
NCT07617753 2026-06-01

DUAL-OV-CAR-NK

Beijing Biotech

Phase 1/2 Recruiting
36 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence

NCT03017131 2026-04-06

Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Roswell Park Cancer Institute

Phase 1 Active not recruiting
9 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06483048 2026-03-16

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

Mayo Clinic

Phase 1 Recruiting
12 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡